Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Abatacept or Placebo (both as IV & SC solution), Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 5
States / cities: Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more

Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions: Varicella Zoster Vaccine, Placebo Injection; Biological · Other
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more

Conditions: Takayasu's Arteritis, Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 15 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, placebo, methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more

Conditions: Rheumatoid Arthritis, Chronic Hepatitis B
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Asthma
Interventions: abatacept, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lupus Nephritis
Interventions: BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more

Conditions: Systemic Lupus Erythematosus
Interventions: Abatacept, Placebo, Prednisone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Covid19
Interventions: Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021); Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 18 Years and older
Enrollment: 1,971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 67
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Systemic Lupus Erythematosus
Interventions: Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CTLA-4 Ig, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Psoriasis Vulgaris
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1996
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: COVID-19, SARS-CoV-2
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Sjogrens Disease
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 19
States / cities: Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more

Conditions: Myositis, Interstitial Lung Disease
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Juvenile Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 10
States / cities: Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more

Conditions: Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions: Abatacept, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 15 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 42
States / cities: Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Search by objective public record fields.

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Immune Modulators for Treating COVID-19

Study of COYA 302 for the Treatment of ALS

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Effects of Abatacept in Patients With Early Rheumatoid Arthritis